Table 1.
Patient baseline characteristics in relation to ABMR category
| Characteristics | Overall cohort (n = 715) | Available data (n) | ABMR+ (n = 46) | Available data (n) | ABMR- (n = 669) | Available data (n) | p-value |
|---|---|---|---|---|---|---|---|
| Recipient data | |||||||
| Age (years), median (IQR) | 48 (37-58) | 715 | 47 (29-54) | 46 | 48 (38-58) | 669 | 0.15 |
| Female sex, % (n) | 37 (267) | 715 | 52 (24) | 46 | 36 (243) | 669 | 0.04 |
| Previous kidney transplantation, % (n) | 16 (115) | 715 | 33 (15) | 46 | 15 (100) | 669 | 0.003 |
| Donor data | |||||||
| Age (years), median (IQR) | 49 (39-58) | 682 | 46 (30-59) | 44 | 49 (39-58) | 638 | 0.51 |
| Non heart beating donor, % (n) | 5 (33) | 715 | 9 (4) | 46 | 4 (29) | 669 | 0.16 |
| Living donor, % (n) | 20 (139) | 695 | 18 (8) | 45 | 20 (131) | 650 | 0.85 |
| Extended criteria donor, % (n) | 28 (184) | 659 | 26 (11) | 42 | 28 (173) | 617 | 0.86 |
| Transplant data | |||||||
| HLA (A, B, DR) mismatch (n), median (IQR) | 3 (2-4) | 679 | 3 (2-3) | 45 | 3 (2-4) | 634 | 0.95 |
| ABO incompatibility, % (n) | 2 (16) | 715 | 0 | 46 | 16 (2) | 669 | 0.62 |
| CDCXM conversion, % (n) | 2 (17) | 715 | 13 (6) | 46 | 2 (11) | 669 | <0.001 |
| Current CDC-PRA >10%, % (n) | 9 (60) | 658 | 19 (8) | 43 | 8 (52) | 615 | 0.05 |
| Preformed DSA, % (n) | 28 (75) | 264 | 83 (20) | 24 | 23 (55) | 240 | <0.001 |
| Cold ischemia time (hours), median (IQR) | 13 (8-19) | 635 | 12 (9-18) | 43 | 13 (8-19) | 592 | 0.85 |
| Delayed graft function, % (n) | 16 (117) | 715 | 17 (8) | 46 | 16 (109) | 669 | 0.84 |
ABMR, antibody-mediated rejection; IQR, interquartile range; CDCXM, complement dependent cytotoxicity cross match; CDC-PRA, complement dependent cytotoxicity panel reactive antibody; DSA, donor specific antibodies.